Antibody–drug conjugates (ADCs) are rapidly reshaping the oncology treatment landscape. By combining the targeting precision of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, ADCs offer the promise of improved efficacy with more controlled toxicity. This potential has fueled...
Every year on February 4th, the world comes together to recognize World Cancer Day, a global initiative led by the Union for International Cancer Control (UICC). This day unites individuals, communities, and organizations in the fight against cancer while raising...
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape for certain hematological malignancies, offering hope where conventional therapies have been exhausted. By reprogramming a patient's own T-cells to recognize and attack cancer cells, CAR-T therapy embodies the promise...
Dose escalation studies are pivotal in the early phases of clinical drug development for evaluating the safety profile of a new therapeutic agent and identifying a recommended dose for further investigation. These studies lay the groundwork for understanding the pharmacokinetic...
Adaptive design is a progressive approach that utilizes different statistical modeling to allow for modifications to enrollment in a clinical trial after study initiation without undermining data integrity and validity. This methodology is particularly beneficial and increasingly common in phase...
Hematological malignancies are a diverse group of cancers that affect the blood, bone marrow, lymph nodes, and spleen. The complexity and variability of these diseases demand innovative and personalized approaches to treatment that traditional clinical trial methodologies often lack. Designing...
In the field of oncology, as we got better at understanding the changes that occur in cancers at a molecular level, we have seen a shift towards precision medicine. Biomarkers are central to this change and can be leveraged to...
Advances in genomic and proteomic technologies have led to the identification of numerous biomarkers with potential clinical utility in oncology, including gene mutations, gene amplifications, gene expression signatures, and altered proteins. To date, more than 1,500 potential oncology biomarkers have...
Prostate cancer (PC) is one of the most commonly diagnosed cancers overall and the most frequently diagnosed cancer in men. The 2018 global estimate of new PC cases exceeded 1.2 million, and more than 350,000 men died from the disease...
Minimizing the burden that trial participants experience is essential for successful recruitment and retention, especially in oncology studies, where patients may need to be followed for years after the treatment phase of the trial. For sponsors, the process of optimizing...